Aardvark Therapeutics (AARD) Competitors $8.49 +0.31 (+3.79%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock AARD vs. OCS, ABUS, SNDL, GHRS, TBPH, PROK, VIR, MNMD, KURA, and KALVShould you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Oculis (OCS), Arbutus Biopharma (ABUS), SNDL (SNDL), GH Research (GHRS), Theravance Biopharma (TBPH), ProKidney (PROK), Vir Biotechnology (VIR), Mind Medicine (MindMed) (MNMD), Kura Oncology (KURA), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. Aardvark Therapeutics vs. Its Competitors Oculis Arbutus Biopharma SNDL GH Research Theravance Biopharma ProKidney Vir Biotechnology Mind Medicine (MindMed) Kura Oncology KalVista Pharmaceuticals Oculis (NASDAQ:OCS) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk. Does the media prefer OCS or AARD? In the previous week, Oculis had 3 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 8 mentions for Oculis and 5 mentions for Aardvark Therapeutics. Oculis' average media sentiment score of 0.74 beat Aardvark Therapeutics' score of -0.14 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Is OCS or AARD more profitable? Aardvark Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -13,958.12%. Aardvark Therapeutics' return on equity of 0.00% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-13,958.12% -90.31% -67.85% Aardvark Therapeutics N/A N/A N/A Do analysts prefer OCS or AARD? Oculis currently has a consensus price target of $35.75, indicating a potential upside of 108.33%. Aardvark Therapeutics has a consensus price target of $32.60, indicating a potential upside of 283.98%. Given Aardvark Therapeutics' higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in OCS or AARD? 22.3% of Oculis shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation and earnings, OCS or AARD? Aardvark Therapeutics has lower revenue, but higher earnings than Oculis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$780K960.52-$97.43M-$2.67-6.43Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A SummaryAardvark Therapeutics beats Oculis on 6 of the 10 factors compared between the two stocks. Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AARD vs. The Competition Export to ExcelMetricAardvark TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$177.48M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.71%4.51%P/E RatioN/A7.5859.1122.53Price / SalesN/A458.96547.00119.09Price / CashN/A44.5237.0558.92Price / BookN/A9.9310.916.06Net Income-$20.59M-$53.38M$3.29B$266.28M7 Day PerformanceN/A0.05%0.01%-0.76%1 Month Performance-32.08%7.08%7.06%3.83%1 Year PerformanceN/A11.92%50.09%24.39% Aardvark Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AARDAardvark TherapeuticsN/A$8.49+3.8%$32.60+284.0%N/A$177.48MN/A0.0018News CoverageOCSOculis2.5566 of 5 stars$16.15-1.2%$35.75+121.4%+35.7%$705.11M$780K-6.052Short Interest ↑ABUSArbutus Biopharma2.5964 of 5 stars$3.66-0.4%$5.50+50.5%-1.5%$700.66M$6.17M-12.6090News CoveragePositive NewsSNDLSNDL3.487 of 5 stars$2.66-1.3%$4.00+50.7%+27.9%$697.67M$944.25M-9.832,516News CoverageAnalyst ForecastHigh Trading VolumeGHRSGH Research2.2408 of 5 stars$13.37-3.4%$32.00+139.4%+42.9%$693.20MN/A-18.0010News CoverageTBPHTheravance Biopharma3.6468 of 5 stars$13.80-1.3%$21.33+54.6%+71.6%$691.95M$64.38M57.25110Positive NewsPROKProKidney3.3701 of 5 stars$2.34-6.6%$6.25+167.7%-1.7%$687.14M$80K-4.103News CoverageVIRVir Biotechnology3.2145 of 5 stars$4.93-2.3%$28.44+477.6%-29.2%$685.55M$14.39M-1.23580News CoverageAnalyst ForecastInsider TradeMNMDMind Medicine (MindMed)2.5312 of 5 stars$8.91-8.9%$24.71+177.5%+56.2%$679.18MN/A-5.8340News CoveragePositive NewsKURAKura Oncology3.8395 of 5 stars$7.81-3.2%$24.10+208.6%-58.3%$676.78M$53.88M-3.45130News CoveragePositive NewsAnalyst ForecastKALVKalVista Pharmaceuticals4.0623 of 5 stars$13.36-1.1%$26.29+96.8%+14.5%$672.29MN/A-3.62100News CoveragePositive News Related Companies and Tools Related Companies OCS Alternatives ABUS Alternatives SNDL Alternatives GHRS Alternatives TBPH Alternatives PROK Alternatives VIR Alternatives MNMD Alternatives KURA Alternatives KALV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AARD) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
